Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target
Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.
RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target
RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
Goldman Sachs Maintains Buy on Charles Schwab, Lowers Price Target to $75
Goldman Sachs analyst Alexander Blostein maintains Charles Schwab (NYSE:SCHW) with a Buy and lowers the price target from $98 to $75.
Analyst Ratings for Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Analyst Ratings for Globe Life
Over the past 3 months, 8 analysts have published their opinion on Globe Life (NYSE:GL) stock. These analysts…
RBC Capital Reiterates Sector Perform on Paysafe, Maintains $36 Price Target
RBC Capital analyst Daniel Perlin reiterates Paysafe (NYSE:PSFE) with a Sector Perform and maintains $36 price target.
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics – 1-for-18 Reverse Stock Split
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy, 1-for-18 reverse stock split.
RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.
JMP Securities Reiterates Market Outperform on Vacasa, Maintains $3 Price Target
JMP Securities analyst Eric Ross reiterates Vacasa (NASDAQ:VCSA) with a Market Outperform and maintains $3 price target.
RBC Capital Maintains Sector Perform on AcuityAds Holdings, Raises Price Target to C$3.5
RBC Capital analyst Drew McReynolds maintains AcuityAds Holdings (TSX:AT) with a Sector Perform and raises the price target from C$3 to C$3.5.